Get to know our clinical trials
Trial of tarlatamab in combination with durvalumab vs. durvalumab monotherapy in subjects with extended stage small cell lung cancer after platinum, etoposide and durvalumab.
THIS STUDY IS BEING CONDUCTED TO LEARN MORE ABOUT TREATMENT WITH TARLATAMAB AND DURVALUMAB OR DURVALUMAB ALONE IN PEOPLE WITH EXTENDED-STAGE SMALL CELL LUNG CANCER (ESSCLC), A DISEASE IN WHICH CANCER CELLS FORM IN THE TISSUES OF THE LUNG AND SPREAD TO OTHER PARTS OF THE BODY SUCH AS THE OTHER LUNG, BONES, BRAIN OR BONE MARROW.
Technical Summary
- PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER, OPEN-LABEL STUDY OF TARLATAMAB IN COMBINATION WITH DURVALUMAB VERSUS DURVALUMAB ALONE IN SUBJECTS WITH EXTENDED-STAGE SMALL-CELL LUNG CANCER AFTER TREATMENT WITH PLATINUM, ETOPOSIDE AND DURVALUMAB (DELLLPHI-305). IMMUNOTHERAPY
- Code EudraCT: 2023-505989-29
- Protocol number: 20200041
- Promoter: Amgen, S.A.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.